Zheng Guo | Pharmacology | Best Researcher Award

Prof. Zheng Guo | Pharmacology | Best Researcher Award

Prof. Zheng Guo, Second Hospital of Shanxi Medical University, China.

Prof. Zheng Guo πŸŽ“, a renowned anesthesiologist and cardiovascular researcher, holds an M.B. from Shanxi Medical College and a Ph.D. from the University of Leeds. He has served as President of Shanxi Medical University and currently leads its Anesthesiology Department. His research focuses on myocardial ischemia, pain, and the autonomic nervous system πŸ«€πŸ§ . With multiple NSFC grants and publications in top-tier journals, Prof. Guo is a trailblazer in medical science and an inspiration to future researchers πŸ”¬πŸ“š.

Profile

Scopus Profile

Orcid Profile

πŸŽ“ Early Academic Pursuits

Prof. Zheng Guo began his academic journey with an M.B. from Shanxi Medical College in Taiyuan, China (1978–1983), laying a strong foundation in clinical medicine. Driven by a passion for scientific inquiry, he pursued a Ph.D. at the University of Leeds, UK (1988–1991), where he conducted pioneering research under the mentorship of Professor C.S. Goodchild. His early exposure to both clinical and translational research positioned him for a career at the intersection of medicine and science.

πŸ₯ Professional Endeavors

Prof. Guo has had an illustrious career spanning decades at Shanxi Medical University. He served as President (2000–2009) and earlier as Acting President (1998–2000), steering academic growth and institutional reform. Since 1994, he has chaired the Departments of Anesthesiology at The Second Hospital of Shanxi Medical University and has been a Professor of Anesthesiology since 1997. His enduring commitment to teaching, leadership, and clinical excellence continues to inspire the next generation of medical professionals.

πŸ”¬ Contributions and Research Focus On PharmacologyΒ 

Prof. Guo’s research centers on critical physiological mechanisms underlying myocardial ischemia/reperfusion injury, diabetes, stress responses, and the autonomic and sensory nervous systems, especially in relation to pain. His studies have elucidated how neurogenic and neuropeptidergic pathways affect cardiac health, with implications for anesthetic practices and cardiovascular therapies.

🌍 Impact and Influence

Prof. Guo’s work has significantly influenced both basic and clinical sciences in cardiology and anesthesiology. Through his dual leadership in research and education, he has elevated the global reputation of Shanxi Medical University. His mentorship has shaped numerous clinicians and researchers, contributing to the academic growth of the field in China and abroad.

🧠 Research Skills

Prof. Guo possesses comprehensive expertise in experimental cardiovascular pharmacology, pain modeling, neurophysiological assays, and animal model validation. His command over complex research methodologies and interdisciplinary collaboration has enabled groundbreaking discoveries in pain and cardiac injury mechanisms.

πŸ… Awards and Honors

Throughout his career, Prof. Guo has been recognized for his excellence in research and education. Although specific honors are not listed here, his leadership roles and consistent funding from prestigious bodies like the National Natural Science Foundation of China (NSFC) stand as testaments to his scientific and professional distinction.

Publications Top Notes

πŸ“„ Comprehensive validation of a custom three-point bending system for standardized diabetic fracture models in rats
πŸ‘¨β€πŸ”¬ Guo Q., Wang W., Guo Z.
🧬 Journal of Orthopaedic Surgery and Research, 2025
πŸ”§πŸ€ Focus: Diabetic fracture models, biomechanics

πŸ§ͺ Morphine timing-dependent modulation of TRPV1 phosphorylation correlates with differential morphine effects on myocardial ischemia/reperfusion injury
πŸ§‘β€πŸ”¬ Wang X., Li X., Jiang B., Wang T., Guo Z.
πŸ’‰ European Journal of Pharmacology, 2024
❀️‍πŸ”₯πŸ’Š Focus: Morphine effects on heart injury and TRPV1 receptor modulation

πŸ’” Epidural administration of large dose of opioid ΞΌ receptor agonist may impair cardiac functions and myocardial viability via desensitizing transient receptor potential vanilloid 1
πŸ§ͺ Ma X., Guo Z., Li M., Wang T., Sun T.
πŸ«€ Toxicology and Applied Pharmacology, 2024
πŸ§ πŸ’” Focus: Cardiac effects of high-dose opioids and TRPV1 receptor desensitization

πŸ«€ Antagonism of N/OFQ attenuates externalization of Ξ²1-adrenergic receptor and ventricular arrhythmias in acute myocardial ischemia rat model
πŸ”¬ Han Y., Xiong C., Zhang L., Yang G., Guo Z.
πŸ’‰ European Journal of Pharmacology, 2022
⚑❀️ Focus: Arrhythmia prevention through N/OFQ antagonism

πŸ•’ Impact of timing of morphine treatment on infarct size in experimental animal model of acute myocardial ischemia and reperfusion
πŸ§‘β€πŸ”¬ Lei Y., Li X., Guo Z.
🫁 European Journal of Pharmacology, 2022
β±οΈπŸ«€ Focus: Morphine timing and myocardial infarct size

Yuan Ma | Pharmacology | Best Researcher Award

Dr. Yuan Ma | Pharmacology | Best Researcher AwardΒ 

Dr. Yuan Ma, Hong Kong Baptist University, Netherlands.

Ma Yuan (Ph.D.) is a Research Assistant Professor at the Institute for Precision Medicine and Innovative Drug, Hong Kong Baptist University. He specializes in aptamer-based translational research and drug discovery, with expertise in nucleic acid chemistry, advanced organic chemistry, and tumor pharmacology. Dr. Ma earned his Ph.D. from Peking University, focusing on nucleoside lipid delivery for oligonucleotides. With over 34 publications, his research has significantly advanced cancer therapeutics and targeted drug delivery. His work continues to shape innovative biomedical applications.

Professional Profile

Scopus Profile

Orcid Profile

πŸŽ“ Early Academic Pursuits

Ma Yuan demonstrated an early passion for pharmaceutical sciences, embarking on his academic journey at Peking University. He earned a Bachelor of Science (2009-2013), majoring in organic chemistry, pharmacology, and pharmaceutical analysis. Advancing his expertise, he pursued a Master of Science (2013-2015) at the Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University, focusing on DNA synthesis, medicinal chemistry, and tumor pharmacology. His master’s thesis explored the stability of D-/L-IsoNA modified siRNA under the mentorship of Prof. Zhenjun Yang. Driven by a deep interest in nucleic acid chemistry and drug development, Ma Yuan completed a Doctor of Philosophy (2015-2019) at the same institution, where he investigated novel nucleoside lipid delivery for single-stranded oligonucleotides, again under Prof. Zhenjun Yang.

πŸ’Ό Professional Endeavors

Building on his strong academic foundation, Ma Yuan transitioned into cutting-edge research and drug discovery. His professional career began as an Associate Research Fellow (2019-2020) at the Mengchao Hepatobiliary Hospital of Fujian Medical University, where he focused on nucleic acid-based diagnostics and treatment for primary liver cancer. He then moved to Hong Kong Baptist University, serving as a Postdoctoral Research Fellow (2020-2022) and later as a Research Assistant Professor (2022-Present) at the Institute for Precision Medicine and Innovative Drug. His work in aptamer-based translational research and drug discovery has made significant contributions to the field of targeted therapy and precision medicine.

πŸ”¬ Contributions and Research Focus On PharmacologyΒ 

Ma Yuan’s research is deeply embedded in the development of aptamer-based therapeutics, a revolutionary approach in cancer treatment and drug delivery. His work bridges organic chemistry, nucleic acid chemistry, and pharmacology, leading to breakthroughs in tumor-targeted therapies, nucleic acid-based drug modifications, and controlled drug release mechanisms. He has developed peptide aptamer-drug conjugates, explored hypoxia-potentiating agents, and innovated in bone anabolic aptamer therapies.

🌍 Impact and Influence

With a multidisciplinary approach spanning pharmaceutical chemistry, cancer therapy, and precision medicine, Ma Yuan’s research is shaping the future of personalized healthcare. His findings have contributed to improving drug efficacy, reducing side effects, and enhancing targeted delivery systems, significantly impacting the field of oncology and regenerative medicine.

πŸ“š Academic Citations & Publications

Ma Yuan has authored over 34 research papers in high-impact journals, including Acta Materia Medica, Cancer Letters, Journal of Medicinal Chemistry, and Molecular Therapy Nucleic Acids. His work has been cited extensively, reinforcing his influence in the field of nucleic acid drug discovery. His contributions as a first author, co-first author, and corresponding author highlight his leadership in scientific research.

πŸ… Awards and Honors

Throughout his career, Ma Yuan has received numerous accolades recognizing his excellence in pharmaceutical sciences and translational research. His research in aptamer-functionalized drug delivery systems and targeted cancer therapies has earned him global recognition.

πŸš€ Legacy and Future Contributions

As a pioneering researcher in nucleic acid-based therapies, Ma Yuan continues to push the boundaries of aptamer technology. His ongoing work in translational medicine, drug development, and biomolecular engineering promises to revolutionize cancer treatment, targeted drug delivery, and precision medicine. With his innovative approach and commitment to scientific advancement, he is set to leave a lasting impact on the future of personalized medicine.

Publications Top Notes

  1. Machine Learning-Powered, High-Affinity Modification Strategies for Aptamers πŸ§ πŸ”¬

    • Journal: Acta Materia Medica
    • Year: 2025 πŸ“…
  2. Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy πŸŽ―πŸ’Š

    • Journal: Pharmaceutics
    • Year: 2024 πŸ“…
  3. Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics 🦴🧬

    • Journal: Journal of Medicinal Chemistry
    • Year: 2024 πŸ“…
  4. Targeting Osteoblastic 11Ξ²-HSD1 to Combat High-Fat Diet-Induced Bone Loss and Obesity πŸ”βž‘οΈπŸ¦΄

    • Journal: Nature Communications
    • Year: 2024 πŸ“…
  5. Aptamer Functionalized Hypoxia-Potentiating Agent and Hypoxia-Inducible Factor Inhibitor Combined with Hypoxia-Activated Prodrug for Enhanced Tumor Therapy 🎯🦠

    • Journal: Cancer Letters
    • Year: 2024 πŸ“…
  6. Sclerostin Inhibition in Rare Bone Diseases πŸ¦΄πŸ’Š

    • Journal: Journal of Orthopaedic Translation
    • Year: 2024 πŸ“…
  7. Advancing Targeted Combination Chemotherapy in Triple Negative Breast Cancer: Nucleolin Aptamer-Mediated Controlled Drug Release πŸŽ―πŸ’Š

    • Journal: Journal of Translational Medicine
    • Year: 2024 πŸ“…
  8. Small RNAs in Cancer Therapy πŸ§¬πŸŽ—οΈ

    • Book Chapter: Interdisciplinary Cancer Research
    • Year: 2024 πŸ“…
  9. Aptamer AS411 Interacts with the KRAS Promoter/hnRNP A1 Complex and Shows Increased Potency Against Drug-Resistant Lung Cancer πŸ«πŸ’Š

    • Journal: RSC Medicinal Chemistry
    • Year: 2024 πŸ“…
  10. Design and Synthesis of Nucleotidyl Lipids and Their Application in the Targeted Delivery of siG12D for Pancreatic Cancer Therapy 🎯🩸

  • Journal: Biomedicine and Pharmacotherapy
  • Year: 2024 πŸ“…
  1. Unique Quinoline Orientations Shape the Modified Aptamer to Sclerostin for Enhanced Binding Affinity and Bone Anabolic Potential πŸ¦΄πŸ”¬
  • Journal: Molecular Therapy – Nucleic Acids
  • Year: 2024 πŸ“…
  1. The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates πŸ§ͺ🩺
  • Book Chapter: Drug Metabolism and Pharmacokinetics
  • Year: 2024 πŸ“…
  1. Intracellular Sclerostin Plays a Vital Role in Tumor Progression and Metastasis in Triple-Negative Breast Cancer πŸŽ—οΈπŸ¦ 
  • Journal: Cancer Research
  • Year: 2024 πŸ“